To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT ID: NCT00141245
Last Updated: 2007-01-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
325 participants
INTERVENTIONAL
1998-10-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
NCT00141388
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00141336
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
NCT00143143
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00150293
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
NCT00141414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Deakin, Australian Capital Territory, Australia
Pfizer Investigational Site
Chatswood, New South Wales, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia
Pfizer Investigational Site
Maroochydore, Queensland, Australia
Pfizer Investigational Site
Heidelberg, , Australia
Pfizer Investigational Site
Woodville, , Australia
Pfizer Investigational Site
Graz, , Austria
Pfizer Investigational Site
Innsbruck, , Austria
Pfizer Investigational Site
Duffel, , Belgium
Pfizer Investigational Site
Helsinki, , Finland
Pfizer Investigational Site
Turku, , Finland
Pfizer Investigational Site
Lyon, Cedex, France
Pfizer Investigational Site
Paris, Cedex, France
Pfizer Investigational Site
Tours, Cedex, France
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Roubaix, , France
Pfizer Investigational Site
Erlangen, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Göttingen, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Mainz, , Germany
Pfizer Investigational Site
Mönchengladbach, , Germany
Pfizer Investigational Site
Munich, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Pavia, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Pisa, , Italy
Pfizer Investigational Site
Heemstede, , Netherlands
Pfizer Investigational Site
Heeze, , Netherlands
Pfizer Investigational Site
Parow, Cape Town, South Africa
Pfizer Investigational Site
Durban, , South Africa
Pfizer Investigational Site
Girona, Gerona, Spain
Pfizer Investigational Site
Donostia / San Sebastian, Guipuzcoa, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Lavigny, LE, , Switzerland
Pfizer Investigational Site
Tschugg, , Switzerland
Pfizer Investigational Site
Bimingham, , United Kingdom
Pfizer Investigational Site
Bucks, , United Kingdom
Pfizer Investigational Site
Dundee, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Liverpool, , United Kingdom
Pfizer Investigational Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1008-012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.